This chemical trick could turn losing malaria drug into a winner
Peer-Reviewed Publication
Updates every hour. Last Updated: 7-Oct-2025 17:11 ET (7-Oct-2025 21:11 GMT/UTC)
Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the Mount Sinai Health System. By giving clinicians advance notice, this approach may enhance patient care and the patient experience, reduce overcrowding and “boarding” (when a patient is admitted but remains in the ED because no bed is available), and enable hospitals to direct resources where they’re needed most. Among the largest prospective evaluations of AI in the emergency setting to date, the study published in the July 9 online issue of the journal Mayo Clinic Proceedings: Digital Health [https://doi.org/10.1016/j.mcpdig.2025.100249].
New research finds troubling gaps in the accuracy and fairness of mental health screenings used with incarcerated youth who have been adjudicated delinquent in the U.S. With a significant number of them entering correctional facilities and already facing serious mental health challenges, including high rates of depression and suicide risk, proper identification and timely intervention are critical. However, research findings suggest that the most used screening tools may not be as reliable for everyone as once believed.
The R21/Matrix-M malaria vaccine generates nearly identical antibodies as those following a natural infection, helping explain why the vaccine confers such strong protection against the earliest life stage of malaria parasites, according to research published in the Journal of Experimental Medicine.
Hepatocellular carcinoma (HCC), the most common liver cancer, includes aggressive subtypes resistant to treatment. Researchers from Institute of Science Tokyo, Japan, identified a key mechanism behind one such subtype and developed a mouse model replicating its characteristics. Their study found that combining angiogenesis inhibitors with immune checkpoint blockers effectively disrupted the tumor’s defenses, enabling immune cells to attack. These findings offer a promising strategy for improving treatments and outcomes for patients with aggressive HCC.